About Tanreqing mezlocillin sulbactam injection combined treatment of community acquired pneumonia clinical observation.docVIP

 PAGE \* MERGEFORMAT 7 About Tanreqing mezlocillin sulbactam injection combined treatment of community acquired pneumonia clinical observation [Abstract] Objective To observe Tanreqing mezlocillin sulbactam injection combined treatment of community acquired pneumonia (CAP) The clinical efficacy and safety. Way to be our hospital 90 cases of community acquired pneumonia were randomly divided into two group, treatment group 45 cases, control group 45 patients received routine expansion in the bronchus, expectorant, oxygen therapy, based on control group mezlocillin sulbactam treatment group Tanreqing Injection Combined with merlot西林舒巴坦 treatment. Results The total effective rate in treatment group 84.4%, control group, the total effective rate was 64.4%, the statistical comparison, the difference was statistically significant (P lt;0.05), both groups after treatment No adverse reaction occurred. Conclusion Tanreqing mezlocillin sulbactam combined treatment of community acquired pneumonia results were satisfactory, and no significant adverse reactions, is worthy of clinical use.  Community-acquired pneumonia (community-acquired pneumonia, CAP) refers to hospital suffering from inflammation of lung parenchyma infection, including infection with a clear incubation period of pathogens in the hospital an average incubation period after the onset of pneumonia is a common community-acquired disease. I Tanreqing injection combined with mezlocillin and sulbactam treatment of community acquired pneumonia, access to good effect. these are as follows: 1 Materials and Methods 1.1 General information  Select January-December 2010 in our hospital 90 patients with community-acquired pneumonia, are in line with the Chinese Medical Association credits will be developed respiratory disease diagnostic criteria of the disease   [1]  .90 patients were randomly assigned to treatment group and the control group, 45 patients in each group, treatment group, 22 males and 23